日本語 >>
TOP page
Present specialized field
Journal
Presentation
Belonging society
（Last updated : 2021-07-28 15:30:56）
Takuya Fukazawa
Department
Kawasaki Medical School Kawasaki Medical School, Department of General Surgery,
Position
Associate Professor
■
Present specialized field
Molecular biology
■
Journal
1.
2018/06
Development of an integrated CRISPRi targeting Np63 for treatment of squamous cell carcinoma.
2.
2017/11
Targeted silencing of SOX2 by an artificial transcription factor showed antitumor effect in lung and esophageal squamous cell carcinoma.
3.
2017/10
Targeted silencing of SOX2 by an artificial transcription factor showed antitumor effect in lung and esophageal squamous cell carcinoma.
4.
2017/03
Gene signature driving invasive mucinous adenocarcinoma of the lung.
5.
2017/02
A Case of Cholesterol Crystal Embolization with Hemorrhagic Imntestinal Ulcer
6.
2017/02
Evaluation of intra-ductal cancer spread using contrast superb micro-vascular imaging(SMI)-a case report-
7.
2016/10
A Case of Birt-Hogg-Dube (BHD) Syndrome Harboring a novel Folliculin (FLCN
) Gene mutation.
8.
2016/06
Novel Midkine Inhibitor iMDK Inhibits Tumor Growth and Angiogenesis in Oral Squamous Cell Carcinoma.
9.
2016/02
SOX2 suppresses CDKN1A to sustain growth of lung squamous cell carcinoma
10.
2015/07
A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor.
11.
2015/06
Skin Tube Reconstruction for Esophageal Defects due to Postoperative Complications: Applying a skin flap in esophageal
resection and reconstruction
12.
2014/12
A case report of isolated presacral squamous cell carcinoma developd four years after gastrectomy
13.
2014/12
Amino acid signaling in the intestine: The roles of glutamine, leucine and arginine
14.
2014/08
A case of autoimmune pulmonary alveolar proteinosis appearing as a localized ground-glass opacity.
15.
2014/02
Preclinical evaluation of micro RNA-34 b/c delivery for malignant pleural mesothelima.
16.
2014/01
Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma.
17.
2013/12
A Case of Acute Superior Mesenteric Artery Embolism with Severe Ischemic Liver Injury Successfully Treated by Endovascular Treatment.
18.
2013/11
Gastric function preserving esophagectomy for esophageal cancer
19.
2013/11
Successful treatment of a lung cancer patient with factor XI deficiency
20.
2013/08
Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancers
21.
2013/01
Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice.
22.
2013/01
Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer
23.
2012/12
Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung.
24.
2012/11
Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma.
25.
2012/09
Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer.
26.
2012/07
Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity.
27.
2012/07
Giant gastrointestinal stromal tumor of the jejunum resected after treatmentwith imatinib
28.
2012/07
Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer.
29.
2010/12
Targeting KRAS mutation-bearing lung cancer
in vivo
by pulmonary surfactant-adenovirus-mediated gene transfer.
30.
2010/11
Anti-tumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and retinoic acids.
31.
2010/10
Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc.
32.
2010/09
Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction.
33.
2010/07
HSP90 and its inhibitors.
34.
2010/04
Can it become a potential therapeutic target?
35.
2010/04
RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.
Display 5 items
Display all(35)
■
Presentation
1.
2018/09/28
Targeted silencing of SOX2 by an ATF showed antitumor effect in lung and esophageal squamous cell carcinoma （Poster notice）
2.
2018/04/16
Targeted silencing of SOX2 by an artificial transcription factor showed antitumor effect in lung and esophageal squamous cell carcinoma （Poster notice，General）
3.
2017/10/16
TGFALPHA PROMOTES GROWTH OF LUNG TUMORS CARRYING EGFR MUTATION BUT NOT KRAS MUTATION IN TRANSGENIC MOUSE MODELS IN VIVO （Poster notice）
4.
2017/04/03
Development of a novel targeted therapy for malignant mesothelioma carcinoma by a midkine inhibitor. （Poster notice）
5.
2016/10/06
SOX2 suppresses CDKN1A to sustain growth of lung squamous cell carcinoma （Speech，General）
6.
2016/04/18
Sox2 silencing upregulates CDKNIA and suppresses growth of lung squamous cell carcinoma （Poster notice）
7.
2015/04/21
Developmemt of a Sox2 targeting therapy for the treatment of lung squamous cell carcinoma （Poster notice，General）
8.
2014/09/27
Sox2 silencing suppresses cell growth and colony formation of
squamous cell lung cancer （Poster notice，Panelist at Symposium/Workshop (Applied)）
9.
2014/04/06
Effective use of MDK/Midkine and MEK inhibitor to treat KRas mutated pulmonary adenocarcinoma cells （Poster notice，General）
10.
2014/04/04
Inhibition of the growth factor midkine by a novel small molecule compound to treat pulmonary adenocarcinoma （Speech，General）
11.
2013/10/05
Inhibition of Midkine by a novel small molecule compound to treat non-small cell lung cancer （Speech，General）
12.
2013/06/19
THE USEFULNESS OF THE LEFT LATERAL DECUBITUS POSITION IN THE THORACOSCOPIC ESOPHAGECTOMY
13.
2013/04/08
Development of novel targeted therapies for non-small cell carcinoma by novel Midkine inhibitors （Poster notice，General）
14.
2012/09/21
Identification of novel Midkine inhibitors for the treatment of non-small cell lung cancer （Speech，General）
15.
2012/04/04
Targeting KRAS lung cancer in vivo by pulmonary surfactant-medicated gene transfer （Poster notice，General）
16.
2012/04/02
HSP90 inhibitor NVP-AUY922 exhibits the potent antiproliferative effect in gastrointestinal cancer cells with a lack of PTEN expression （Poster notice，General）
17.
2011/10/03
Anti-tumor effect in lung cancer by a combination treatment of novel HDAC inhibitors : SL142 or SL325 and retinoic acids （Speech，General）
18.
2011/04/14
The impact of adenoviral gene transfer of microRNA-34b/c on malignant pleural mesotheliomas
19.
2011/04/04
Antitumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and retinoic acids. （Poster notice）
20.
2011/04/04
Inhibition of mammalian target of rapamycin(mTOR)signaling by Temsirolimus as a potential therapeutic strategy for esophageal cancer treatment. （Poster notice）
21.
2010/09/24
Targeting KRAS lung cancer in vivo by pulmonary surfactant-mediated gene transfer （Panelist at Symposium/Workshop (Other)）
22.
2010/04/18
Adenoviral mediated expression of Omomyc induced growth inhibition and apoptosis in lug cancer expressing Myc
Display 5 items
Display all(22)
■
Belonging society
1.
American Association for Cancer Research
